BioSpace News Archive

Favorable tolerability profile consistent with Phase 1 data.

ZIOPHARM is advancing its non-viral Sleeping Beauty (SB) platform towards point-of-care (P-O-C) for very rapid manufacturing of genetically modified CAR+ T cells.

Mesoblast Limited has been named by Frost & Sullivan as the 2017 Global Technology Leader in the Cell Therapy Industry.

The data are being presented today in an oral presentation at the 2017 ASH Annual Meeting.

Sernova plans to initiate the new clinical trial under this US IND to investigate the Cell Pouch for tT1D in individuals with hypoglycemia unawareness.

The initial dose escalation data suggest that the combination of zanubrutinib and tislelizumab had a manageable toxicity profile and anti-tumor activity in patients with B-cell malignancies.

Actimab-A is the lead candidate from Actinium’s CD33 Program.

The dividend for the first quarter of 2018 will be $0.5625 per share on outstanding common stock.

The financing was led by Apollo Ventures, a Life Sciences Venture Capital firm and Life Sciences Company builder working across Europe and North America.

City of Hope patients whose acute myeloid leukemia (AML) was no longer responding to standard therapies and a patient with a rare blood cancer, blastic plasmacytoid dendritic cell neoplasm, achieved a complete response (cancer-free) after undergoing treatment with MB-102 CAR-T therapy, which targets CD123 cells.